The FDA has approved Apellis Pharma-ceuticals’ complement protein C3 inhibitor pegcetacoplan for paroxysmal nocturnal haemoglobinuria (PNH). With this approval the pegylated cyclic peptide will now compete with Alexion/AstraZeneca’s first-in-class blockbuster anti-C5 antibody eculizumab in this rare disease. But complement modulators could have activity in common diseases too.

Para acessar a publicação na íntegra clique aqui